Referred to the House Committee on Energy and Commerce.
This resolution is a formal statement adopted by the House of Representatives recognizing Charcot-Marie-Tooth disease and urging robust research funding at the National Institute of Neurological Disorders and Stroke. It expresses the House's view and priorities but does not create law or appropriate funds. Because it is only a House resolution, it does not require the President's signature and is not binding federal policy. In practice it raises awareness and signals support to health agencies and lawmakers who decide budgets.
This is a simple resolution passed within the House only; it does not go to the Senate or the President and is non-binding. It does not change statutes or authorize spending on its own.
This House resolution recognizes Charcot-Marie-Tooth disease (CMT) as a significant inherited peripheral neuropathy affecting thousands in the U.S. and millions worldwide.
It urges robust research funding at the National Institute of Neurological Disorders and Stroke (NINDS/NIH) and continued investment in CMT and other rare disease research; it is a symbolic, non‑binding statement and contains no appropriation language.
As drafted (H.Res.), it is non-binding and cannot become law; any legal effect would require separate legislative action.
Relative to its intended legislative type, this bill is a standard non‑binding House resolution that clearly identifies Charcot‑Marie‑Tooth disease and expresses support for increased research funding at NINDS. It provides clear problem statements but contains no binding mechanisms, fiscal authorizations, implementation steps, or accountability measures — features that are generally not expected for a symbolic resolution.
Lib-left pushes for concrete federal funding increases; conservatives want offsets.
These are examples from the analysis, not a ranked list of the most-affected groups.
Lib-left pushes for concrete federal funding increases; conservatives want offsets.
Likely strongly supportive because the resolution calls for increased federal research funding for a rare disease and highlights a funding shortfall.
They will view it as consistent with priorities for expanded NIH investment, health equity, and support for underserved disease communities.
They may nonetheless press for concrete appropriation commitments and access provisions.
Generally favorable but pragmatic; views the resolution as useful awareness-raising for a documented disease and a prompt to evaluate NINDS funding.
Wants clear budgetary paths, measurable outcomes, and bipartisan buy‑in before supporting concrete spending increases.
Sees symbolic value but demands fiscal realism.
Cautiously supportive of research and constituent advocacy but skeptical about federal spending expansion.
Prefers private‑sector and state solutions and will oppose unfunded federal commitments.
Views the resolution as acceptable if it remains symbolic and does not obligate appropriations.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
As drafted (H.Res.), it is non-binding and cannot become law; any legal effect would require separate legislative action.
The bill has not accumulated any surfaced votes yet.
Lib-left pushes for concrete federal funding increases; conservatives want offsets.
As drafted (H.Res.), it is non-binding and cannot become law; any legal effect would require separate legislative action.
Relative to its intended legislative type, this bill is a standard non‑binding House resolution that clearly identifies Charcot‑Marie‑Tooth disease and expresses support for increased research funding at NINDS. It provi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.